2026-02-10, 7:12:50 a.m.
QUÉBEC, Feburary 10, 2026. — Leads & Copy —
Devonian Health Group Inc. (TSXV: GSD); (OTCQB: DVHGF) announced today that preclinical data has demonstrated proof of concept efficacy for Thykamine™ in an animal model of pulmonary fibrosis, suggesting a potential expanded therapeutic application.
The clinical stage corporation is focused on developing solutions to fibroinflammatory diseases.
The study investigated the effects of Thykamine™ in a bleomycin-induced pulmonary fibrosis (IPF) mouse model. Researchers administered Thykamine™ orally at doses of 0.05, 0.1, 0.25, 0.5, and 1 mg/kg, and benchmarked against pirfenidone dosed at 220 mg/kg over a 21-day period.
The animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring.
Thykamine™ demonstrated statistically significant antifibrotic activity in the bleomycin-induced pulmonary fibrosis model. Pirfenidone did not reach statistical significance in physiological endpoints.
Treatment with Thykamine™ at 0.5 mg/kg significantly reduced lung wet weight and lung tissue index compared with the bleomycin/vehicle group.
Bleomycin exposure led to marked increases in fibrosis and inflammation compared with sham controls. Thykamine™ treatment significantly reversed these pathological changes, reducing both fibrosis and inflammation scores and indicating meaningful improvement in lung morphology.
Thykamine™ at 0.5 mg/kg produced a statistically significant downregulation of key fibrosis- and inflammation-associated genes, including Fn1 (fibronectin), Col1a1, Col3a1, Col6a1, and Col6a3 (collagen isoforms involved in extracellular matrix deposition), Birc5, and the chemokines Ccl2 and Cxcl2 (inflammatory cell recruitment).
Thykamine™ significantly increased Mmp9, a matrix metalloproteinase associated with extracellular matrix turnover, while reducing Mmp13, a collagenase often linked to progressive tissue injury and inflammation.
According to the company, this gene expression profile is consistent with controlled matrix remodeling and attenuation of fibrotic progression, positioning Thykamine™ as a next-generation therapeutic candidate in pulmonary fibrosis.
The company plans to present data in an upcoming scientific publication.
Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of lung tissue. It leads to declining respiratory function and premature mortality.
Thykamine™ is the first pharmaceutical product issued from Devonian’s SUPREX™ platform, for the prevention and treatment of health conditions related to fibroinflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions.
Devonian is traded publicly on the TSX Venture Exchange (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).
“These results represent a major inflection point for Thykamine™,” said Dr. Andre P. Boulet, PhD, Chief Executive Officer. “The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model, but also significantly broaden Thykamine™’s mechanism of action. By combining potent anti-inflammatory and anti-fibrotic activity at low doses, Thykamine™ demonstrates clear potential to address the underlying biology of fibro-inflammatory diseases and to serve as a scalable, multi-indication platform with disease-modifying potential.”
Source: Devonian Health Group Inc.
